202 related articles for article (PubMed ID: 37780688)
1. Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas.
Cacciapuoti S; Potestio L; Guerrasio G; Fabbrocini G; Scalvenzi M; Ruggiero A; Caiazzo G; Megna M
Clin Cosmet Investig Dermatol; 2023; 16():2637-2644. PubMed ID: 37780688
[TBL] [Abstract][Full Text] [Related]
2. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
3. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
4. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy.
Tampouratzi E; Sfaelos K; Talaiporou K; Douvali Τ; Katsantonis J
Acta Dermatovenerol Croat; 2023 Aug; 31(1):48-50. PubMed ID: 37843093
[TBL] [Abstract][Full Text] [Related]
5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
6. Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: A Narrative Review.
Cannizzaro MV; Coscarella G; Chiricozzi A
Dermatol Pract Concept; 2023 Jul; 13(3):. PubMed ID: 37557129
[TBL] [Abstract][Full Text] [Related]
7. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
8. Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.
Menter A; Bhutani T; Ehst B; Elewski B; Jacobson A
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1289-1302. PubMed ID: 35672564
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
Seo SJ; Shin BS; Lee JH; Jeong H
J Dermatol; 2021 Jun; 48(6):807-817. PubMed ID: 33373480
[TBL] [Abstract][Full Text] [Related]
10. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis).
Gargiulo L; Ibba L; Malagoli P; Amoruso F; Argenziano G; Balato A; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Fabbrocini G; Franchi C; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Megna M; Sampogna F; Travaglini M; Costanzo A; Narcisi A
Front Med (Lausanne); 2023; 10():1196966. PubMed ID: 37469659
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis.
Papp K; Menter A; Strober B; Kricorian G; Thompson EH; Milmont CE; Nirula A; Klekotka P
J Am Acad Dermatol; 2015 Mar; 72(3):436-439.e1. PubMed ID: 25553889
[TBL] [Abstract][Full Text] [Related]
12. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
13. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
Puig L
Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
[TBL] [Abstract][Full Text] [Related]
14. Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain.
Galan-Gutierrez M; Font-Ugalde P; Padilla L; Hernandez-Montoya C; Godoy D; Armario-Hita JC; Ruiz-Villaverde R
Int J Dermatol; 2023 May; 62(5):700-706. PubMed ID: 36495585
[TBL] [Abstract][Full Text] [Related]
15. Brodalumab: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2018 Mar; 78(4):495-504. PubMed ID: 29516365
[TBL] [Abstract][Full Text] [Related]
16. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
Kokolakis G; Vadstrup K; Hansen JB; Carrascosa JM
Dermatology; 2022; 238(4):620-629. PubMed ID: 34823247
[TBL] [Abstract][Full Text] [Related]
17. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
Roman M; Chiu MW
Drug Des Devel Ther; 2017; 11():2065-2075. PubMed ID: 28744098
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis.
Galluzzo M; Talamonti M; Cioni A; Maffei V; Shumak RG; Tofani L; Bianchi L; Campione E
J Clin Med; 2022 May; 11(9):. PubMed ID: 35566756
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population.
Sahuquillo-Torralba A; Hospital-Gil M; Vilarrasa-Rull E; Llamas-Velasco M; Rivera R; Carrascosa JM; de la Cueva-Dovao P; Armesto-Santos S; Ruíz-Villaverde R; Velasco-Pastor M; Magdaleno-Tapial J; Yanguas-Bayona JI; Ribera-Pibernat M; Salgado-Boquete L; Herranz-Pinto P; Romero-Mate A; Martínez-Lorenzo E; López-Estebaranz JL; Ballescá-López F; Botella-Estrada R
Australas J Dermatol; 2023 Nov; 64(4):e317-e326. PubMed ID: 37435962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]